Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
HBM Healthcare Investments AG (HBMN.SW)
Zug, CH
HBM Healthcare Investments AG specializes in both direct investments and a fund-of-funds strategy, focusing exclusively on the healthcare sector, encompassing human medicine, pharmaceuticals, biotechnology, diagnostics, and medical technology. Its direct investments target a diverse range of companies, from early-stage startups and various venture and growth phases to mature private enterprises, unlisted emerging firms, and small-cap public entities. The firm also provides capital for company buyouts, growth initiatives, Private Investments in Public Equity (PIPEs), and the spin-off of product lines or departments from larger corporations, as well as the expansion or restructuring of established businesses. Through its fund-of-funds approach, HBM allocates capital to venture capital funds. Initial direct investments are typically made in companies whose primary products are either in clinical development or just prior to that stage. With a global investment mandate, the company emphasizes opportunities in North America, Europe, and the Asia Pacific region. For publicly traded companies, HBM generally prioritizes those that originated within its private investment portfolio. The firm often increases its commitment to portfolio companies through subsequent financing rounds or after their initial public offering. HBM frequently secures a seat on the portfolio company's Board of Directors and may acquire majority stakes. While primarily investing through equity, it also employs various other financial instruments, including convertible bonds, debt securities, structured products, and derivatives. Exits from these investments are typically facilitated through trade sales or initial public offerings.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.21% | +0.00% | +3.96% | +6.53% | +15.65% | +6.29% | +37.18% | +17.96% | -26.55% | +145.33% | +181.55% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Asset Management: +17.4%-100.0% Q1'26: +100.0% (vs Q1'25)
-
EPS growth Asset Management: +22.7%+1,397.8% ★ Q1'26: +68.8% (vs Q1'25)
-
FCF margin FCF growth · Asset Management: +27.7%— ★
-
EBIT margin Asset Management: +50.6%—
-
ROIC Asset Management: +6.5%+14.1% ★ Q1'26: -2.9% (vs Q1'25)
-
Share dilution Asset Management: +0.0%-1.9% ★ Q1'26: -2.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Asset Management: -0.03×0.37× Q1'26: -1.75× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2016 actual |
Mar 2017 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
Mar 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
27.23M
est: 114.62M (-76.2%)
|
142.41M
est: 114.62M (+24.2%)
|
-73.78M
est: -37.50M (-96.8%)
|
-142.25M
est: -107.50M (-32.3%)
|
3.08M
est: -42.40M (+107.3%)
|
22.37M
est: 76.90M (-70.9%)
|
35.10M
35.10M – 35.10M
-54.4% YoY
|
134.40M
134.40M – 134.40M
+282.9% YoY
|
141.60M
141.60M – 141.60M
+5.4% YoY
|
| EBITDA |
25.17M
est: 79.33M (-68.3%)
|
139.20M
est: 79.33M (+75.5%)
|
-78.03M
est: -25.95M (-200.7%)
|
-146.32M
est: -74.40M (-96.7%)
|
-1.08M
est: -29.34M (+96.3%)
|
18.54M
est: 53.47M (-65.3%)
|
24.41M
24.41M – 24.41M
-54.4% YoY
|
93.46M
93.46M – 93.46M
+282.9% YoY
|
98.46M
98.46M – 98.46M
+5.4% YoY
|
| EBIT |
25.17M
est: 79.33M (-68.3%)
|
139.20M
est: 79.33M (+75.5%)
|
-78.03M
est: -25.95M (-200.7%)
|
-146.32M
est: -74.40M (-96.7%)
|
-1.08M
est: -29.34M (+96.3%)
|
18.54M
est: 53.47M (-65.3%)
|
24.41M
24.41M – 24.41M
-54.4% YoY
|
93.46M
93.46M – 93.46M
+282.9% YoY
|
98.46M
98.46M – 98.46M
+5.4% YoY
|
| Net Income |
23.81M
est: 52.66M (-54.8%)
|
136.77M
est: 77.29M (+77.0%)
|
-78.03M
est: -76.35M (-2.2%)
|
-146.32M
est: -135.76M (-7.8%)
|
-1.08M
est: -70.43M (+98.5%)
|
18.54M
est: 48.31M (-61.6%)
|
8.14M
8.14M – 8.14M
-83.1% YoY
|
106.57M
106.57M – 106.57M
+1,209.0% YoY
|
113.71M
113.71M – 113.71M
+6.7% YoY
|
| SGA |
824.0K
est: 17.34M (-95.2%)
|
913.0K
est: 17.34M (-94.7%)
|
1.17M
est: -5.67M (+120.6%)
|
1.10M
est: -16.26M (+106.7%)
|
2.07M
est: -6.42M (+132.2%)
|
2.13M
est: 26.82M (-92.1%)
|
12.24M
12.24M – 12.24M
-54.4% YoY
|
46.88M
46.88M – 46.88M
+282.9% YoY
|
49.39M
49.39M – 49.39M
+5.4% YoY
|
| EPS |
3.11
est: 7.74 (-59.8%)
|
18.96
est: 11.36 (+66.9%)
|
-11.22
est: -11.22 (+0.0%)
|
-21.03
est: -19.95 (-5.4%)
|
-0.16
est: -10.35 (+98.5%)
|
2.72
est: 7.24 (-62.4%)
|
1.22
1.22 – 1.22
-83.1% YoY
|
15.97
15.97 – 15.97
+1,209.0% YoY
|
17.04
17.04 – 17.04
+6.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-21 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 |
| 2026-05-20 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 |
| 2026-05-19 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 |
| 2026-05-18 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 |
| 2026-05-15 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 |
| 2026-05-13 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 |
| 2026-05-12 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 |
| 2026-05-11 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 |
| 2026-05-08 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-05 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-04 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Andreas Wicki | Chief Executive Officer | 172.5K | — |
| Erwin Troxler | Chief Financial Officer | 104.0K | male |
| Alexander G. Asam | Investment Advisor | — | — |
| Benedikt Suter | Secretary to the Board of Directors | — | — |
| Thomas Thaler | Advisor of HBM Partners | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for HBMN.SW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
